Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

Antibacterial Drugs: World Market Prospects 2012-2022

1699

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Site License

Site License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£1,699.00

Change Currency

GBP EURO USD
GBP EURO USD

Market

Healthcare and Medical

Report Type

Market Research

Country

Global

Published

28 November 2011

Number of Pages

167

Report Delivery

Email

Delivery Lead Time

1-3 hours, 24 hour max

Publisher

Visiongain

File Format

PDF

Pfizer, Merck, GSK and Bayer All Aiming for Top Spot in the Global Antibacterial Drugs Market

Dalacin C - Dalacin C (clindamycin, Pfizer) is a macrolide active against anaerobic bacteria. These bacteria tend to form infections in areas of the body such as the gut, pelvic cavity and gums. The drug is reported to have a similar spectrum of antibacterial activity to penicillins and this makes it a useful alternative for people who are allergic to this class. For the first nine months of 2010, Pfizer reported revenue of Dalacin C of $0.17bn. We therefore estimate that it had full-year revenue of $0.22bn.

Revenue for the first three quarters of 2011 was down on that for 2010 to $0.14bn. We forecast that full-year revenue for 2011 will be $0.18bn. Generics of clindamycin are available in major markets, including a version launched by Strides Arcolab in October 2011. Generic competition will cause revenue to fall throughout the forecast period. By 2022, revenue for Dalacin C will be $0.13bn, having fallen with a CAGR of % from 2010.

Meiact - Meiact (cefditoren pivoxil, Meiji Seika Kaisha) is an orally-active cephalosporin antibiotic first launched in the Japanese market in 1994. It is indicated as treatment for a broad-range of infections that include dermatological and community-acquired infections. In 1997, Meiji signed a license agreement with TAP Holdings, a Takeda/Abbott Laboratories joint venture, for the drug in North America. The drug was launched in China in 2001 and in Spain in 2004, and is now available in around 20 countries worldwide. In January 2008, Meiji signed a five-year marketing and distribution agreement with C&O Pharmaceutical Technology (Holdings) in China. Revenues for Meiact in that country are around $5-10m annually.

In October 2006, Meiji entered into an exclusive agreement with Cornerstone Therapeutics for the marketing of Meiact in the US. The drug is marketed as Spectracef there. In 2008 Cornerstone launched a 400mg version of Spectracef onto the US market. The original dosing for the drug was a 200mg tablet. Cornerstone reported US revenue for Spectracef of $9m in 2009. In 2010, however revenue for the region had fallen to $5m.

Introduction

With its R&D pipeline, the antimicrobial drug industry has potential for improved treatment of bacterial diseases. Bacteria still pose a great threat, with antibiotic resistance staying a challenge in clinical practice.

Key Questions Answered

- What are the commercial prospects for antibacterial treatments?
- How will 20 leading products - including Levaquin, Zyvox, Avelox, Augmentin, Zosyn, Merrem, Cubicin, Primaxin and Cravit - perform to 2022?
- What does the future hold?

Report Scope

Discover sales predictions at world market, therapeutic class, product and national levels to 2022. Our report gives you business research, analysis and opinion for the treatment of bacterial infections. This market research report gives forecast values for cephalosporin, penicillin, fluoroquinolone, macrolide and carbapenem submarket, and possible sales trends for antibiotics from 2012.

This study discusses Pfizer, Merck, GSK, Cubist, Abbott, Bayer and other pharmaceutical companies. Receive analyses for anti-infective agents in human healthcare, including hospital-acquired infections. In our report, you find revenue forecasting, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), views and R&D news. You receive 149 tables and charts and two research interviews.

Report Overview

- Find revenue predictions to 2022 for the overall world antibacterial drug market and submarkets, seeing revenue growth
- Discover revenue forecasts to 2022 for 20 leading products, assessing commercial potential
- See revenue forecasts to 2022 for leading national markets - US, Japan, China, India, Brazil, France, Italy, Germany, UK and Spain
- Assess leading companies

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Site License

Site License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£1,699.00

Change Currency

GBP EURO USD

Change Currency

GBP
USD

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

eBrandPromote: Get your brands ranked highly online

eBrandPromote: Let us promote your brand online through article writing, press release distribution, social media and search engine marketing services. Click here to download our eBrandPromote brochure.

Accessibility
Close

Contrast settings

Text size settings